

Oncologic Drugs Advisory Committee

September 10-11, 2001

68th Meeting

Consultants (voting)

For IntraDose:

Marion Everett Couch, M.D., Ph.D.
Assistant Professor
Department of Otolaryngology, Head and Neck Surgery
Johns Hopkins Medical Center, JHOC
601 N. Caroline Street, Suite 6252
Baltimore, MD 21287

Bonnie Glisson, M.D.
Section Chief, Head and Neck Medical Oncology
Department of Thoracic and Head and Neck Medical Oncology
University of Texas M. D. Anderson Cancer Center
1515 Holcombe Boulevard, Box 80
Houston, Texas 77030-4009

Lawrence V. Rubinstein, Ph.D.
Head, Developmental Clinical Trials and Preclinical Studies Section
Biometric Research Branch
National Cancer Institute
6130 Executive Blvd EPN, Room 8130
Rockville, MD 20852

For Zevalin®, (*Consultants – Center for Biologics Evaluation and Research*)

James D. Bridges, M.D.
Maryland Regional Cancer Care LLC
40 West Gude Drive
Rockville, MD 20850

Alexandra M. Levine, M.D.
Professor of Medicine
University of Southern California/Norris Cancer Center
Division of Hematology, MS 34
1441 Eastlake Avenue
Los Angeles, CA 90033

For Gliadel:

Jan Craig Buckner, M.D.
Mayo Medical School
Division of Medical Oncology
200 First Street, SW
Rochester, Minnesota 55905

Howard A. Fine, MD
National Cancer Institute
National Institute of Neurological Disorder and Stroke
Building 10/Room 12S245-MS1911
10 Center Drive
Bethesda, Maryland 20892

Lemuel A. Moye, M.D., Ph.D.
University of Texas Health Sciences Center
Houston School of Public Health
Coordinating Center for Clinical Trials
1200 Herman Pressler St. Suite 801
Houston, Texas 77030

Lawrence V. Rubinstein, Ph.D.
Head, Developmental Clinical Trials and Preclinical Studies Section
Biometric Research Branch
National Cancer Institute
6130 Executive Blvd EPN, Room 8130
Rockville, MD 20852

Patient Representatives (voting)

For *Clinical Trial Designs for First-Line Treatment of Metastatic Breast Cancer*
Musa Mayer - New York, New York

For IntraDose: Glenn Gruett - Appleton, Wisconsin

For Zevalin: Susan Krivacic – Austin, Texas

For Gliadel: Craig Lustig - Washington, D.C.

Oncologic Drugs Advisory Committee

66th Meeting

Industry Representative (non-voting)

George H. Ohye
3 Heritage Hills Court
Skillman, New Jersey 08558-2340

Guests and Guest Speakers (non-voting)

For *Clinical Trial Designs for First-Line Treatment of Metastatic Breast Cancer*

Nancy Davidson, M.D.
Professor of Oncology - Experimental Therapeutics
School of Medicine
Johns Hopkins University (JHU)
East Baltimore Medical Center
1650 Orleans St.
Baltimore, Maryland

I. Craig Henderson, M.D.
School of Medicine
University of California at San Francisco
Breast Cancer Program
Box 1710
San Francisco, California 94143

For Zevalin®:

Ruby F. Meredith, M.D., Ph.D.
Professor, Radiation Oncology
Radiation Oncology Department
University of Alabama – Birmingham Medical School
619 South 19th Street
Birmingham, Alabama 35233-6832